Academic Integrity: tutoring, explanations, and feedback — we don’t complete graded work or submit on a student’s behalf.

SPSS IS REQUIRED TO SOLVE THESE QUESTIONS. PLEASE ANSWER QUESTION 1 TO 5, THERE

ID: 3350341 • Letter: S

Question

SPSS IS REQUIRED TO SOLVE THESE QUESTIONS. PLEASE ANSWER QUESTION 1 TO 5, THERE RESPECTIVE SPSS FILE IS ATTACHED BELOW.

Postpartum Depression

In this assignment we will look at women with birth depression and how estrogen treatment can affect depression. The data is contained in the data depression footprint.

Prior to treatment, all women were assessed after the Edinburgh Postnatal Depression Scale (EPDS). High EPDS scores indicate severe depression. Patients were randomly assigned to either receive placebo (group = 0, n = 18) or estrogen (group = 1, n = 22) as treatment. The EPDS score was again measured after 3 months of treatment.

In this task you should choose whether to perform a regular two-sample T-test / paired t-test, or if you should also perform a non-parametric test (Wilcoxon-Mann-Whitney test / Wilcoxon pairing test) when we To check if treatment has an effect. To determine this, check the assumptions that are the basis for performing a t-test. For a two-sample t-test, make sure that the two samples are normally distributed and for a paired t-test, be sure to check that the difference between the paired data is normally distributed. Do not use log-transformation in this task, even if it is possible.

1- Give a descriptive description of the variables EPDS prior to treatment initiated for each of the treatment groups (placebo and estrogen). Write a brief summary of what you find. Is there a significant difference between the two treatment groups in EPDS score before receiving treatment?

2- Is there a significant difference between the two treatment groups in 3 months of treatment?

3- Just look at those who have received estrogen as treatment. Have they had a significant change in EPDS score from before treatment to after 3 months of treatment?
4- Now look at those who have received a placebo. Have they had a significant change in EPDS score from before treatment to after 3 months of treatment?
5- Check the change from before treatment to after 3 months of treatment for the placebo and estrogen groups. Perform a test and check whether estrogen has had an effect on the EPDS score.

SPPS FILE

BEFORE TREATMENT

18
22
17
15
20
27
28
25
16
26
19
22
16
21
20
22
21
25
21
27
15
24
15
17
20
18
28
21
18
27
19
20
21
23
24
25
28
23
22
23

AFTER TREATMENT

21
24
23
14
17
20
20
28
20
28
14
26
18
22
13
23
18
26
10
13
15
15
17
21
8
14
9
26
9
12
9
9
11
27
10
11
10
13
8
11

GROUP

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

Explanation / Answer

Result:

The difference between before and after is calculated as variable change. The normality test for before score for two groups shows that data follows normal distribution. The normality test for after score for two groups shows that data follows normal distribution. The normality test for difference of score for two groups shows that data does not follows normal distribution.

Tests of Normality

group

Kolmogorov-Smirnova

Shapiro-Wilk

Statistic

df

Sig.

Statistic

df

Sig.

before

placebo

0.133

18

0.200*

0.958

18

0.570

estrogen

0.093

22

0.200*

0.963

22

0.563

after

placebo

0.097

18

0.200*

0.958

18

0.563

estrogen

0.197

22

0.027

0.801

22

0.001

change

placebo

0.230

18

0.013

0.912

18

0.094

estrogen

0.245

22

0.001

0.879

22

0.012

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Give a descriptive description of the variables EPDS prior to treatment initiated for each of the treatment groups (placebo and estrogen). Write a brief summary of what you find. Is there a significant difference between the two treatment groups in EPDS score before receiving treatment?

Group Statistics

group

N

Mean

Std. Deviation

Std. Error Mean

before

placebo

18

21.11

3.924

0.925

estrogen

22

21.77

3.878

0.827

Independent Samples Test

Levene's Test for Equality of Variances

t-test for Equality of Means

F

Sig.

t

df

Sig. (2-tailed)

Mean Difference

Std. Error Difference

95% Confidence Interval of the Difference

Lower

Upper

before

Equal variances assumed

0.000

0.985

-0.534

38

0.596

-0.662

1.239

-3.170

1.847

Equal variances not assumed

-0.533

36.275

0.597

-0.662

1.241

-3.177

1.854

There is no significant difference between the two treatment groups in EPDS score before receiving treatment, t=-0.534, P=0.596.

Is there a significant difference between the two treatment groups in 3 months of treatment?

Group Statistics

group

N

Mean

Std. Deviation

Std. Error Mean

after

placebo

18

20.83

4.630

1.091

estrogen

22

13.09

5.380

1.147

Independent Samples Test

Levene's Test for Equality of Variances

t-test for Equality of Means

F

Sig.

t

df

Sig. (2-tailed)

Mean Difference

Std. Error Difference

95% Confidence Interval of the Difference

Lower

Upper

after

Equal variances assumed

0.048

0.828

4.816

38

0.000

7.742

1.608

4.488

10.997

Equal variances not assumed

4.890

37.882

0.000

7.742

1.583

4.537

10.948

There is a significant difference between the two treatment groups in EPDS score after receiving treatment, t=4.816, P=0.000.

Just look at those who have received estrogen as treatment. Have they had a significant change in EPDS score from before treatment to after 3 months of treatment?

Paired Samples Statisticsa

Mean

N

Std. Deviation

Std. Error Mean

Pair 1

before

21.77

22

3.878

0.827

after

13.09

22

5.380

1.147

a. group = estrogen

Paired Samples Testa

Paired Differences

t

df

Sig. (2-tailed)

Mean

Std. Deviation

Std. Error Mean

95% Confidence Interval of the Difference

Lower

Upper

Pair 1

before - after

8.682

7.253

1.546

5.466

11.898

5.614

21

0.000

a. group = estrogen

There is a significant change in EPDS score from before treatment to after 3 months of treatment, t=5.614, P=0.000.


Now look at those who have received a placebo. Have they had a significant change in EPDS score from before treatment to after 3 months of treatment?

Paired Samples Statisticsa

Mean

N

Std. Deviation

Std. Error Mean

Pair 1

before

21.11

18

3.924

0.925

after

20.83

18

4.630

1.091

a. group = placebo

Paired Samples Testa

Paired Differences

t

df

Sig. (2-tailed)

Mean

Std. Deviation

Std. Error Mean

95% Confidence Interval of the Difference

Lower

Upper

Pair 1

before - after

0.278

4.240

0.999

-1.831

2.386

0.278

17

0.784

a. group = placebo

There is no significant change in EPDS score from before treatment to after 3 months of treatment, t=0.278, P=0.784.

Check the change from before treatment to after 3 months of treatment for the placebo and estrogen groups. Perform a test and check whether estrogen has had an effect on the EPDS score.

Group Statistics

group

N

Mean

Std. Deviation

Std. Error Mean

change

placebo

18

0.2778

4.23994

0.99936

estrogen

22

8.6818

7.25315

1.54638

Independent Samples Test

Levene's Test for Equality of Variances

t-test for Equality of Means

F

Sig.

t

df

Sig. (2-tailed)

Mean Difference

Std. Error Difference

95% Confidence Interval of the Difference

Lower

Upper

change

Equal variances assumed

3.879

0.056

-4.340

38

0.000

-8.40404

1.93624

-12.32375

-4.48433

Equal variances not assumed

-4.564

34.723

0.000

-8.40404

1.84120

-12.14294

-4.66514

The change from before treatment to after 3 months of treatment for the placebo and estrogen groups is significant, t=-4.340, P=0.000.

Tests of Normality

group

Kolmogorov-Smirnova

Shapiro-Wilk

Statistic

df

Sig.

Statistic

df

Sig.

before

placebo

0.133

18

0.200*

0.958

18

0.570

estrogen

0.093

22

0.200*

0.963

22

0.563

after

placebo

0.097

18

0.200*

0.958

18

0.563

estrogen

0.197

22

0.027

0.801

22

0.001

change

placebo

0.230

18

0.013

0.912

18

0.094

estrogen

0.245

22

0.001

0.879

22

0.012

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction